TriangleFOR PATIENTS · SOURCE READING
Treatment of Nodular Lymphocyte–Predominant Hodgkin Lymphoma (NLPHL)
Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 27, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of NLPHL in adults may include:
Source links and citations
Watchful waiting or active surveillance.
Source links and citations
Radiation therapy to the areas of the body with cancer, for patients with early-stage NLPHL.
Source links and citations
Chemotherapy, for patients with advanced-stage NLPHL.
Source links and citations
Targeted therapy with a monoclonal antibody (rituximab).
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice